Reportedly, Tesla (TSLA) is on track to deliver one of its strongest quarters in China, according to the latest retail sales data. As the first electric vehicle manufacturer to cut prices in the country, Tesla is striving to maintain its market share. The figures from China Merchants Bank International reveal that Tesla sold 106,915 units in China from January 1 to March 19, averaging at 1,371 units per day. This is slightly higher than the fourth quarter average of 1,327 units per day when Tesla sold a record 122,038 cars.
While Tesla still has some catching up to do with BYD, which outsold Tesla by over five times in the January-February period, the company is planning to refresh its Model 3 and Model Y in the next two years to improve its product mix. Tesla has also updated the suspension system in the Model Y produced in China since January to offer a smoother ride, a move that has been praised by Tesla fans on social media. Tesla’s marketing in China has been focused on attracting pragmatic buyers by highlighting energy efficiency, safety, and storage space. Tesla did not respond immediately to a request for comment.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
DID YOU KNOW?…
On Monday, March 20, INVO Bioscience (NASDAQ: INVO) announced that it has signed binding agreements to acquire a materially transformative acquisition of the Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5 million in revenue and net income of approximately $1.9 million for the trailing 12-month period ended September 30, 2022.
Wisconsin Fertility Institute is led by internationally renowned and well-respected fertility expert, Dr. Elizabeth Pritts, who will continue to serve as the clinic’s lead physician for a minimum period of three years from the closing of the acquisition. Dual-certified in General Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility, Dr. Pritts completed a surgical fellowship in Advanced Gynecologic Laparoscopy and Hysteroscopy. She is also a national leader in the use of robotic surgery for gynecologic disorders. Dr. Pritts served as an assistant professor in reproductive endocrinology and infertility at the University of Wisconsin Medical School, as a clinical fellow at the University of California at San Francisco, and as an instructor at Yale University School of Medicine. She has authored more than 70 articles for scientific publications and has lectured throughout the world on reproduction and fertility.
Dr. Elizabeth Pritts, M.D., Wisconsin Fertility Institute’s Co-founder
“I’m excited to be teaming up with INVO as a unique and attractive partner to help advance us to the next phase of our practice. INVO’s commercial strategy and patient focus, along with its public-company platform and the INVOcell technology itself, offers an exciting pathway to build value and increase access to an efficient, effective, affordable, and connected experience in reproductive treatment. Our team looks forward to being an integral part of INVO’s long-term growth and success.” Dr. Elizabeth Pritts, Wisconsin Fertility Institute’s co-founder.
Wisconsin Fertility Institute joins INVO’s expanding list of fertility clinics, including operating clinics in Atlanta (Bloom Fertility), Birmingham (Innovative Fertility Specialists) and Monterrey, Mexico (Positib Fertility), as well as future clinics under development, such as the wholly owned INVO Center in Tampa, Florida that is currently under construction. INVO’s revolutionary medical device, the INVOcell, allows fertilization and early embryo development to occur in vivo with the woman’s body and is also available at a growing list of non-affiliated fertility centers in the United States and around the world.